Press Releases Year None2024202320222021202020192018 Aug 28, 2024 Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference Aug 09, 2024 Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Jun 11, 2024 Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH Jun 08, 2024 Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 May 29, 2024 Akero Therapeutics to Present at the Jefferies Global Healthcare Conference May 10, 2024 Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 08, 2024 Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference Apr 30, 2024 Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer Mar 08, 2024 Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Mar 07, 2024 Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 16
Year None2024202320222021202020192018 Aug 28, 2024 Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference Aug 09, 2024 Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Jun 11, 2024 Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH Jun 08, 2024 Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 May 29, 2024 Akero Therapeutics to Present at the Jefferies Global Healthcare Conference May 10, 2024 Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 08, 2024 Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference Apr 30, 2024 Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer Mar 08, 2024 Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Mar 07, 2024 Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 16
Aug 28, 2024 Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Aug 09, 2024 Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Jun 11, 2024 Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
Jun 08, 2024 Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
May 10, 2024 Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Mar 08, 2024 Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Mar 07, 2024 Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
